Biotech Co.* |
Pharma Co. (Country) | Type/Product Area | Terms/Details (Date) |
| | |||
Accelrys Inc. |
Bayer Healthcare AG (Germany) |
Bayer licensed a library of life science modeling software from Accelrys |
The tools will be applied at Bayer centers in Germany and the U.S.; terms were not disclosed (9/8) |
Aclara |
GlaxoSmithKline plc (UK) |
GSK will evaluate Aclara's eTag assays for use in patient selection for certain targeted cancer therapies |
GSK will provide the samples, as well as undisclosed funding (10/5) |
Amarillo |
Nobel Ilac Sanayii Ve TicaretA/S (Turkey) |
Nobel got certain rights to oral low-dose interferon-alpha for treating Behcet's disease |
They will conduct trials in Turkey under an FDA IND; if approved in the U.S. Nobel would have rights in a number of countries in east and southeast Europe, as well as Saudi Arabia (9/14) |
Aradigm Corp. |
Novo Nordisk |
Novo gained all development and manufacturing rights to the AERx insulin diabetes management system, which was the subject of their collaboration |
Novo is paying $55M for the program, which earlier ran into problems in a Phase III trial; it also is offering jobs to 130 Aradigm employees working on the program; the deal calls for Aradigm to be eligible for an adjusted royalty rate on any sales (9/28) |
Arena |
Merck & Co. Inc. |
They extended cardiovascular collaboration until October 2007 and expanded the deal to include a wider range of potential therapies |
Merck purchased $7.5M of Arena stock at a premium price of $8 per share, and will provide $5.7M per year in research funding; the October 2002 deal also was amended to provide higher royalties to Arena (10/20) |
Arexis AB* |
Beiersdorf AG |
Collaboration to develop products for the skin care market |
The agreement followed an R&D collaboration between the companies; terms were not disclosed (10/11) |
Artemis |
Boehringer Ingelheim International GmbH (Germany) |
Service and license agreements in the area of mouse genetics and genomics |
BI got a worldwide, exclusive commercial license and a nonexclusive research license to Artemis' Tetraploid Technology for generating genetically modified mice; terms were not disclosed (10/5) |
Atugen AG* |
Sanofi-Aventis Group (France) |
Collaboration to identify siRNA compounds with therapeutic potential |
Terms of the deal were not disclosed (9/13) |
Australian |
Bioaccelerate Inc. |
They committed to collaborate on a Bioaccelerate prostate cancer compound and ACT's pancreatic cancer drug RP101 |
Bioaccerlate is investing A$1.88M (US$1.4M) in ACT as part of the deal in exchange for 4.9M shares; further terms were not disclosed (10/7) |
Barrier |
HealthPoint Ltd. |
Collaboration on Barrier's Zimycan, an antifungal agent being developed for Candida-associated diaper dermatitis |
HealthPoint gets exclusive rights in the U.S. and Canada, and will fund further development; Barrier is eligible to receive milestone payments and revenue from product sales, and gets rights to new indications (9/13) |
BioImage A/S* |
Merck & Co. Inc. |
Merck got rights to use BioImage's Redistribution technology in drug discovery research |
The technology focuses on intracellular signaling; terms of the deal were not disclosed (9/13) |
Biolex Inc.* |
Centocor Inc. (unit of Johnson & Johnson) |
Expanded deal for Biolex to use its LEX System to express Centocor antibodies |
Two proteins were added to the deal, bring the total to six; Biolex may scale-up and manufacture the proteins following this phase; terms were not disclosed (10/6) |
BioNumerik |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Deal under which Takeda would market Tavocept, a Phase III chemoprotective agent, in the U.S. and Canada |
BioNumerik is getting a $52M equity investment up front and potential milestones; they would share profits, and BioNumerik has a co-promotion right in the U.S. (10/7) |
Cell Signaling |
Sanofi-Aventis Group (France) |
Agreement for a pilot study to identify phosphorylation sites and prospective bio-markers of protein tyrosine kinase targets |
CST's PhosphoScan technology will be used in the deal, terms of which were not disclosed (9/21) |
Cellzome AG* |
Novartis AG (Switzerland) |
Collaboration to identify drug targets and leads in a variety of disease areas |
Novartis will make an equity investment in Cellzome and provide research funding for two years; options afterward could entail licenses, milestone payments and royalties (9/20) |
Cerus Corp. |
BioOne Corp. (Japan) |
Finalized deal under whichBioOne will commercialize the Intercept Blood System for platelets in much of Asia |
They closed a deal first announced in July; Cerus and Baxter each gets $10M total up front and contingent milestone and royalty payments (10/14) |
Chlorogen |
Sigma-Aldrich Corp. |
Deal to produce commercial products from chloroplast transformation technology |
Sigma-Aldrich will fund an undisclosed portion of Chlorogen's efforts to produce four specific proteins in tobacco plants (10/4) |
Collegium |
BTG plc (UK) |
Deal to develop formulations of BTG's combination therapy for treating sleep apnea |
The deal provides for revenue sharing; they plan to establish additional co-development programs (9/28) |
Compound |
Abbott |
Abbott gets nonexclusive rights to use PROfusion technology and certain antibody libraries |
Compound gets an up-front payment and potential milestones and royalties from the deal; Abbott will use the technology to develop antibody leads (9/29) |
Compugen |
Diagnostic Products Corp. |
Deal to develop and sell diagnostic products, with a focus in cancer and cardiovascular areas |
DPC will develop diagnostics based on biomarkers discovered by Compugen; Compugen is entitled to development milestone payments and royalties on sales; it has rights to pursue therapeutic applications of the work (9/8) |
Connetics |
Pierre Fabre Dermatologie (France) |
Pierre Fabre got commercial rights to Olux in Europe (except Italy) and certain countries in Africa and South America |
Connetics gets an up-front license payment, milestone payments and royalties on sales of the corticosteroid, which is approved for dermatology applications; Connetics also got rights of first refusal in the U.S. to a Pierre Fabre dermatology product (9/30) |
Emisphere |
Novartis Pharma AG (Switzerland) |
Deal to develop an oral formulation of recombinant human growth hormone using Emisphere's eligen technology |
Emisphere can get up to $34M during product development and a royalty on sales that increases to double-digit rates (9/23) |
Eurand |
Recordati SpA (Italy) |
Deal to test feasibility of developing a modified-release form of Recodati's hypertension drug lercanidipine (Zanidip) |
Eurand will apply its Diffucaps technology in the deal, terms of which were not disclosed (9/14) |
Euroscreen |
Cisbio International |
Euroscreen will use Cisbio's HTRF cAMP assay to validate recombinant cell lines and membranes expressing GPCRs |
Terms of the deal were not disclosed (9/13) |
Evotec OAI |
Altana AG (Germany) |
Deal to advance the discovery of an Altana kinase target |
Evotec will develop assays, screen compounds and optimize hits under the deal, terms of which were not disclosed (10/6) |
Evotec OAI |
Boehringer Ingelheim GmbH (Germany) |
Three-year deal to jointly identify and develop small-molecule therapeutics acting on selected GPCRs |
Evotec will get undisclosed research payments, discovery and development payments, and royalties on any sales; the initial focus is on CNS diseases (9/8) |
ExonHit |
Mitsubishi Pharma Corp. (Japan) |
Mitsubishi gained a site license for Safe-Hit, a microarray-based system that evaluates toxicity |
The deal follows a one-year evaluation by Mitsubishi; terms were not disclosed (9/15) |
FibroGen Inc.* |
Yamanouchi Pharmaceutical Co. Ltd. (Japan) |
Yamanouchi gets rights in Japan to develop and market FG-2216 and similar FibroGen compounds for treating anemia |
FibroGen retains rights to the erythropoietic small molecule in the rest of the world; terms of the deal were not disclosed (9/24) |
Flamel |
TAP Pharmaceutical Products Inc. |
TAP licensed worldwide rights to Flamel's Micropump technology for use in the delivery of lansoprazole |
Flamel potentially could earn more than $100M in milestone payments, and would receive royalties on any sales; lansoprazole is the active ingredient in TAP's Prevacid (9/16) |
Genaissance |
Merck KGaA (Germany) |
Genaissance acquired rights to the Phase II product vilazodone, a selective serotonin reuptake inhibitor and a 5HT1A partial agonist |
Merck will get up to €36M in Genaissance shares for the initial license fee and milestone payments; Merck also would get royalties on all sales, and a share of any sublicensing income (9/23) |
GenOway* |
Pfizer Inc. |
GenOway will generate genetically modified rat model for Pfizer researchers in the U.S. |
The model in an undisclosed area will be based on GenOway's nuclear transfer technology; terms were not disclosed (9/30) |
Gen-Probe |
bioMerieux (France) |
bioMerieux can access Gen-Probe's ribosomal RNA $4.5M if bioMerieux exercises options to technologies for certain uses, and Gen-Probe gets access to technology for detecting mutations implicated in blood-clotting disorders |
Gen-Probe gets $0.25M, and would get develop diagnostic products; bioMerieux could pay another $3M for rights to other targets; Gen-Probe is paying $1M for its nonexclusive, worldwide license; the deals also include royalty provisions; bioMerieux also ended their deal to develop assays for its VIDAS instrument (10/6) |
Genstruct Inc.* |
Berlex Inc. (unit of Schering AG; Germany) |
Collaboration to characterize the regulatory mechanisms of breast cancer |
Genstruct will use its Molecular Epistemics discovery platform in the effort, terms of which were not disclosed (9/15) |
Glycart |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Agreement to develop next- generation antibodies using GlycoMAb technology |
Roche will have the option to develop anti- bodies from the undisclosed product candidate; Glycart gets an up-front fee, research funding and potential milestones and royal- ties (9/21) |
GNI Ltd.* |
Toyama Chemical Co. Ltd. (Japan) |
Deal to use GNI's gene regulatory network technology platform in Toyama's drug development efforts |
GNI licensed the use of a network to Toyama and also will offer its services in the deal, terms of which were not disclosed (10/11) |
Ingex LLC* |
Sigma-Aldrich Corp. |
Deal to provide a gene-disruption technology named TargeTron |
The first system will be developed for the creation of permanent gene knockouts across a range of prokaryotes; terms were not disclosed (10/13) |
International |
Rosetta Inpharmatics LLC (unit of Merck & Co.Inc.) |
Rosetta got a nonexclusive license to ITI's ProxiQuant enzymatic application |
The worldwide license covers R&D applications; terms were not disclosed (9/28) |
Isis |
Eli Lilly and Co. |
Lilly licensed LY2275796, an antisense cancer drug that targets eukaryotic initiation factor-4E |
The drug was discovered in their existing collaboration; Isis gets a $750,000 license fee and potential development and regulatory milestones, as well as royalties on any sales (9/20) |
Kereos Inc.* |
The Dow Chemical Co. |
Deal to further develop and market targeted imaging agents for diagnosis of cancer and cardiovascular disease |
In a deal expansion, Kereos gets rights to chelating molecules and certain technology, while Dow can use molecules created in the collaboration in other applications; terms were not disclosed (9/21) |
Medarex Inc. (MEDX) |
Pfizer Inc. |
Collaboration to discover and develop up to 50 antibody products over 10 years; they also cross-licensed patents on anti-CTLA-4 antibodies |
Pfizer will pay $80M up front and purchase $30M of Medarex stock; Medarex could get research funding, license fees and milestone payments of more than $400M if all 50 products get approved, as well as royalties on any sales (9/20) |
Morphochem AG* and Migragen i.L.* (both of Germany) |
Schering AG (Germany) |
Schering purchased all rights to a patent application covering Rho-kinase inhibitors |
The application also covers new uses for known compounds discovered using Morphochem technologies; terms were not disclosed (9/20) |
NascaCell IP |
Aventis SA (France) |
To use NascaCell's aptamers to improve validation of Aventis targets |
Terms of the deal were not disclosed (9/13) |
NascaCell IP |
Merz |
To use NascaCell's aptamers to improve validation of targets for products in Merz's pipeline |
Terms of the deal were not disclosed (8/30) |
Nastech |
Merck & Co. Inc. |
Global alliance to develop and sell Peptide YY 3-36 Nasal Spray, Nastech's Phase I product for treating obesity |
Nastech will get $5M up front and be eligible to receive up to $131M in development and approval milestones, and up to $210M in sales-related milestones; Nastech also would get royalties on sales (9/27) |
Nobex Corp.* |
Biocon Ltd. |
Agreement to co-develop an oral insulin product for the treatment of diabetes |
The effort combines the peptide oral delivery and process technology of Nobex with the peptide production capabilities of Biocon; terms were not disclosed (10/20) |
Norak |
Purdue Pharma LP |
Purdue got rights to use Norak's Transfluor technology for GPCR-based drug discovery |
Norak will develop cell lines expressing an orphan GPCR target of interest to Purdue, and then screen the cell line against a Purdue compound library; terms were not disclosed (10/13) |
Norak |
Merck & Co. Inc. |
Merck got rights to use Norak's Transfluor technology for GPCR-based drug discovery |
Merck will use the technology broadly in its research; Merck in 2002 had gained limited access to Transfluor; terms were not dis- closed (10/6) |
ObeTherapy |
Zambon Group SpA (Italy) |
Collaboration to identify low-molecular-weight drugsfor treating metabolic disorders |
The research is focused on a target involved in intestinal lipid absorption; terms of the deal were not disclosed (10/8) |
Ortec |
Cambrex Corp. |
Cambrex will market and distribute Orcel, a wound care product being developed by Ortec, in the U.S. |
Cambrex will manage the entire sales process in the U.S. under undisclosed terms; a year ago they entered a six-year deal for Cambrex to manufacture the product (10/18) |
Oy Jurilab Ltd.* |
Summit Pharmaceuticals International Corp. (Japan) |
Collaboration to promote Jurilab's technologies and products in Japan |
Summit will represent Jurilab in Japan for agreements in the areas of disease gene discovery and pharmacogenetics; terms were not disclosed (9/6) |
Paion GmbH* |
Nippon Shinyaku (except Japan) to Shinyaku's (Japan) |
Paion got worldwide rights potential milestones, as well royalties on investigational stroke drug Enecadin |
Shinyaku gets an up-front payment and any sales; Shinyaku kept coexclusive rights in Japan (10/7) |
ParAllele |
Novartis Pharma AG (Switzerland) |
Deal to discover genetic variations associated with coronary artery disease |
Novartis will use resulting markers in drug discovery, and ParAllele will retain rights in diagnostic applications; terms were not disclosed (10/5) |
Perlegen |
GlaxoSmithKline plc (UK) |
Perlegen will perform a high- density whole- genome scanning project for GSK |
Terms of the deal were not disclosed (10/12) |
Physiomics |
Bayer Technology Services (Germany) |
Deal to use their systems biology technologies in a collaboration on clinical response prediction |
They plan to undertake consulting projects for others under undisclosed terms (9/14) |
Protein Design |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Worldwide agreement to co-develop and commercialize Zenapax (daclizumab) for asthma and related respiratory diseases; the deal follows Phase II trial results |
PDL will receive $17.5M up front and up to $187.5M in development and commercialization milestones; they will share development expenses and co-promote the product in the U.S.; PDL would get royalties on sales outside the U.S. (9/16) |
Sangamo |
LifeScan Inc. (unit of Johnson & Johnson) |
LifeScan will use Sangamo's zinc finger DNA- finding proteins to develop therapeutic cell lines |
LifeScan will use the lines in a program to develop a diabetes treatment; terms of the deal were not disclosed (9/30) |
Seattle |
Bayer Pharmaceuticals Corp. |
Bayer licensed ADC technology to link cell- billing drugs to antibodies against a tumor target |
Seattle Genetics gets $2M up front along with potential milestone and royalty payments; it also could earn research support payments (9/28) |
Serono SA |
Undisclosed entity |
The unnamed entity licensed an undisclosed, noncore technology from Serono |
Serono said it would receive a license fee payable over three years; it will recognize $67M as royalty revenue in 3Q:04 from the deal (9/3) |
7TM Pharma |
Synaptic Pharmaceutical Co. (unit of H. Lundbeck by Synaptic A/S; Denmark) |
7TM will apply its structure-based drug discovery approach to 7TM receptors provided |
7TM will use its Site-Directed Drug Discovery technology in the deal, terms of which were not disclosed (9/6) |
7TM Pharma |
AstraZeneca plc (UK) |
7TM will apply its structure-based drug discovery approach to AstraZeneca targets |
7TM will use its Site-Directed Drug Discovery technology in the deal, terms of which were not disclosed (8/30) |
Sienabiotech |
Wyeth Pharmaceuticals |
Deal to research and develop compounds for Alzheimer's disease and other neuro-degenerative diseases |
Sienabiotech gets up-front and potential milestone and royalty payments, and rights to develop products for orphan indications; Wyeth gets worldwide rights to compounds it selects for further development (10/7) |
Sopherion Therapeutics |
Zeneus Pharma Ltd. (UK) |
Sopherion gained North American rights to Myocet, a liposome-encapsulated doxorubicin formulation |
Sopherion plans to launch Myocet in Canada in 2005, and to conduct additional trials in the U.S.; terms of the deal were not disclosed (9/23) |
Structural GenomiX Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration using SGX's FAST technology for the discovery of small-molecule antiviral inhibitors |
SGX gets an undisclosed up-front payment and research funding, as well as potential milestone and royalty payments (9/9) |
TransTech Pharma Inc.* |
Merck & Co. Inc. |
Collaboration to use Trans- Tech's translational technology to discover and develop small molecules for a Merck target |
TransTech could get $26M in milestone and other payments if a drug were approved for the top indication; it also could get payments for other molecules in other indications; Merck has exclusive rights, and would pay royalties on any sales (9/8) |
VistaGen Therapeutics Inc.* |
Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) |
VistaGen will apply embryonic stem cell technology to develop discovery tools for Sanwa, which will use them in diabetes research |
VistaGen will get research payments for at least two years, and milestone payments up to $15M per product, as well as royalties on any sales; VistaGen also retains commercial rights for certain candidates (10/13) |
Wilex AG* |
Centocor Inc. (unit of Johnson & Johnson) |
Wilex got an option to acquire exclusive U.S. marketing rights to the antibody Rencarex (WX-G250) |
Centocor gets an option fee and is eligible for milestone payments and royalties; Wilex gained rights to the Phase III cancer product outside the U.S. from Centocor in 1999 (10/8) |
ViroPharma Inc. (VPHM) |
Eli Lilly and Co. |
ViroPharma is buying U.S. rights to manufacture and market the approved oral antibiotic Vancocin Pulvules |
Lilly will get $116M in cash, and royalties on sales; the product is approved to treat enter- ocolitis caused by S. aureus and antibiotic-associated pseudomembranous colitis caused by C. difficile; sales in 2003 were $40M (10/18) |
Xenon |
Novartis Pharma AG (Switzerland) |
Deal to research, develop and market compounds from Xenon's stearoyl-CoA desaturase-1 drug development program targeting obesity |
Xenon could receive up to $157M in pre- commercialization payments, as well as royalties on any sales; Novartis will fund work at Xenon for at least two years and make an equity investment; Xenon retains an option to certain co-promotion rights (9/21) |
XenoTech LLC* and MultiCell Technologies Inc. (OTC BB:MUCL) |
Eisai Co. Ltd. (Japan) |
Eisai received a three-year license to use Fa2N-4 hepatocytes for internal testing purposes |
Eisai entered the six-figure deal with Nosan Corp., which got rights in Japan from Xeno- Tech, the exclusive licensee from MultiCell (10/18) |
ZymoGenetics |
Novo Nordisk A/S (Denmark) |
Novo acquired exclusive worldwide rights to Zymo-Genetics' recombinant Factor XIII portfolio |
ZymoGenetics gets $15M up front and up to $62M in milestone payments; it also gets a royalty on any Novo sales of products containing recombinant Factor XIII (10/5) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
